Global Cardiovascular Drugs Market: Overview
Diseases related to heart and blood vessels are known as cardiovascular diseases (CVD), these diseases are projected to affect population at large across age, ethnicity and economical condition. According to World Health Organization, cardiovascular diseases are most prevalent causes of death across the world, it estimates that around 31% of the deaths in 2015 were caused by cardiovascular diseases. CVD’s related to heart are heart failure, rheumatic heart diseases, myocardial infarction, arrhythmia, etc. while CVD’s related to blood vessels are atherosclerosis, ischemic stroke, etc. Drugs used to treat these conditions vary with the type of CVD, drug’s mode of action and patient’s health. According to the report, global cardiovascular drugs market stood at US$142.56 bn in 2016 and slated to be worth US$162.96 bn by 2025, as the market is likely to exhibit a CAGR of 1.5% between 2017 and 2025.
According to American Heart Association, around 2,200 people in the U.S. lose their lives to CVDs every year. Furthermore, about 85.6 million people in the country are living with a certain form of cardiovascular disease or after-effects of stroke. Changing dietary habits, increasing consumption of tobacco & alcohol and pollution across the globe is estimated to rise the incidences of CVD’s during the forecast period from 2017 to 2025. This is likely to drive expansion of global cardiovascular drugs market during the forecast period. However, patent expiry of blockbuster cardiovascular drugs and increasing foray of generic drugs is anticipated to hamper the growth of cardiovascular drugs market during the forecast period.
Retail Pharmacies Segment to Augment Market Growth
The global cardiovascular drugs market is segmented on the basis of drug class, distribution channel and geography. On the basis of drug class, the market is segmented into anti hyperlipidemics, anti hypertensives, antiarrhythmatics, anticoagulants, antifibrinolytics and other. The others segment include drugs such as cardiac glycosides, antianginal drugs, and antiischemic drugs. The antihypertensives segment is projected to hold dominating share in global cardiovascular drugs market during the forecast period and is likely to register a moderate growth from 2017 to 2025. Based on distribution channel, global market is segmented into retail pharmacies, hospital pharmacies, and online pharmacies. Retail pharmacies segment is projected to hold prominent share of global cardiovascular drugs market and is projected to grow at CAGR of 1.5% during the forecast period from 2017 to 2025.
North America and Asia Pacific to Make Significant Impact on Global Market
Geographically, the global cardiovascular drugs market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to dominate the global market owing to high prevalence of cardiovascular diseases, high per capita healthcare expenditure and comparatively higher cost of cardiovascular drugs in the region. Europe is projected to account for prominent share of global cardiovascular drugs market during the forecast period owing to well established health care infrastructure and increasing incidences of cardiovascular diseases. Asia Pacific with its considerably established market such as Japan and emerging markets such as India and China is projected to witness an exponential growth during the forecast period.
Some of the key players in the global cardiovascular drugs market are AstraZeneca plc, Allergan plc, Pfizer, Inc., Novartis AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Bayer AG, Sanofi, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Gilead Sciences, Inc., Johnson & Johnson, Astellas Pharma, Inc., Eli Lilly & Co., Otsuka Holdings Co., Ltd., and Takeda Pharmaceutical Company Limited.
Global Cardiovascular Drugs Market: Scope and Methodology
This report on the global cardiovascular drugs market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments.
The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2017 to 2025, considering the macro and micro environmental factors. Growth rates for each segment within the global cardiovascular drugs market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.
A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global cardiovascular drugs market across regions.
Market revenue in terms of US$ Mn for the period between 2015 and 2025 along with the compound annual growth rate (CAGR %) from 2017 to 2025 are provided for all the segments, considering 2016 as the base year and 2015 as historic year. Market size estimations involved in-depth study of product features of different drug class and various pipeline products. Additionally, market related factors such as preference for self-medication, regional availability of specialty drugs, patent expiration of cardiovascular drugs & availability of generic drugs, projected launch of new drugs etc. in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.
Cardiovascular Drugs Market: Segmentation
Cardiovascular diseases are estimated to affect population across the globe. Cardiovascular diseases comprise diseases and disorders related to heart and blood vessels. Various drugs are available and are under development for treating cardiovascular diseases based on various indications, such as arrhythmia, myocardial infarction, atherosclerosis, etc.
Based on drug class, the global cardiovascular drugs market has been segmented into anti hyperlipidemics, anti-hypertensives, anti-coagulants, anti-fibrinolytics, anti-arrhythmic, and others. The others segment of drug class include drugs such as cardiac glycosides, antianginal drugs, and ant ischemic drugs. Anti-hypertensive drugs segment is projected to hold dominant share of global cardiovascular drugs market while anti-hyperlipidemics segment is likely to register steady growth during the forecast period from 2017 to 2025.
Based on the distribution channel, the global cardiovascular drugs market is segmented into retail pharmacies, hospital pharmacies and online pharmacies. High incidences of hospital visits for cardiovascular disease consultation and rise in emergency department visits is likely to contribute for steady growth of hospital pharmacies segment.
Cardiovascular Drugs Market: Geographical and Competitive Dynamics
Geographically, the global cardiovascular drugs market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented by major countries from each region.
The report also profiles major players in the cardiovascular drugs market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include AstraZeneca plc., Pfizer Inc., Novartis AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Bayer AG, Sanofi, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Gilead Sciences, Inc., Johnson & Johnson, Astellas Pharma, Inc., Eli Lilly and Company, Otsuka Holdings Co., Ltd., Takeda Pharmaceutical Company Limited.
The global cardiovascular drugs market has been segmented as below:
Global Cardiovascular Drugs Market, by Drug Class
- Anti hyperlipidemics
- Others ( Cardiac Glycosides, antianginal drugs, anti-ischemic drugs)
Global Cardiovascular Drugs Market, by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Global Cardiovascular Drugs Market, by Geography
- North America
- Rest of Europe
- Asia Pacific
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa